Stryker Corporation (SYK) falls 11.7% after guidance cut
Stryker Corporation (SYK) falls sharply after hours after reporting solid Q3 results but trimming full-year guidance. The medical-device giant still posted growth, yet investors focused on the lower outlook, premium valuation, and earnings quality concerns.
Stryker Corporation (SYK) falls 11.7% in after-hours trading after its Q3 earnings report and a reduced full-year outlook disappointed investors. The company still delivered solid sales and adjusted profit growth, but the guidance reset and premium valuation triggered a sharp selloff. For investors, the move signals higher execution risk and less room for error despite Stryker’s strong medical-device franchise.
Stryker Corporation (SYK) falls sharply in after-hours trading, with the latest extended-hours print at $274.79, down 11.75% from the prior regular close of $311.36. The move follows Stryker’s October 29, 2026, third-quarter earnings report and lower full-year guidance, while regular-session trading will confirm whether the decline holds.
Key Takeaways
The main catalyst is Stryker’s Q3 earnings report and trimmed 2026 outlook, not a broad medical-device sector move.
Q3 sales rose 7.7% to $6.5 billion, while adjusted EPS increased 10.3% to $3.52.
Reported EPS fell 11.7% to $1.96, highlighting acquisition, amortization, and restructuring costs beneath the adjusted result.
Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90.
The business remains strong, but a 31.5 P/E leaves less room for guidance resets and execution mistakes.
The specific catalyst is Stryker’s third-quarter 2026 earnings report, released on October 29. The company posted $6.5 billion in net sales, up 7.7% year over year. Organic sales also grew 7.7%.
Those figures look healthy in isolation. However, Stryker said the quarter fell short of its expectations. That statement matters because it signals an internal performance gap, even with solid growth across the portfolio.
The forward outlook delivered the sharper blow. Stryker now projects 6.5% to 7.0% organic net sales growth for the full year. It also expects adjusted EPS between $14.80 and $14.90. The company revised both measures from its earlier outlook.
That combination explains the aggressive after-hours response. Investors can tolerate a strong quarter with a small blemish. They react differently when management also lowers the path ahead. Intraday volume reached 3.06 million shares, well above a normal session for a large-cap medical-device company.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Stryker’s Q3 Earnings Changed the Growth Story
Stryker’s earnings mix was uneven rather than broadly weak. Adjusted EPS climbed 10.3% to $3.52. Meanwhile, reported EPS dropped 11.7% to $1.96.
The gap reflects acquisition and integration costs, amortization of purchased intangibles, structural optimization charges, and other items. Adjusted earnings show the operating trend more cleanly. Still, the reported decline adds another layer of concern for shareholders assessing earnings quality.
The segment figures offer important balance. MedSurg and Neurotechnology delivered 9.2% reported growth and 9.1% organic growth. Orthopaedics grew 5.7% on a reported basis and 5.9% organically.
These results support Stryker’s competitive position in surgical equipment, navigation, patient safety, emergency care, and orthopaedic products. They also show why the selloff is about expectations rather than a collapse in demand. The business continues to grow, but the market wanted more from a premium medical-technology franchise.
Why SYK’s Valuation Makes the Guidance Reset Matter
Stryker entered the report with a market capitalization of $119.43 billion and a P/E ratio of 31.5. That valuation reflects confidence in durable medical-device demand, product innovation, and Stryker’s ability to gain share.
A premium multiple also raises the cost of disappointment. When management lowers its growth and earnings outlook, investors often reduce the multiple before they question the long-term business. In plain English, the market is paying less for each unit of expected profit because execution now carries more weight.
Recent analyst data shows that confidence had already become more measured. BTIG lowered its Stryker price target from $358 to $316 on October 12. Truist cut its target from $340 to $310 on October 6. The broader analyst consensus still stood at Buy, with 36 Buy ratings, 15 Holds, and one Strong Buy.
That mix creates a useful distinction. Analysts still recognize a quality company, but price targets had moved lower before the earnings shock. A strong company and a strong stock are not always the same thing, especially when valuation assumes steady delivery.
What the Stryker Outlook Means for Investors
The best response is to separate operating strength from valuation risk. Stryker still produced 7.7% organic growth, and both major operating areas expanded. MedSurg and Neurotechnology grew organically by 9.1%, while Orthopaedics posted 5.9% organic growth.
For existing shareholders, the central test is whether the $14.80 to $14.90 adjusted EPS outlook fits the original investment thesis. A lower forecast does not erase the company’s competitive advantages. It does, however, reduce the margin for execution errors.
For prospective buyers, the 11.75% after-hours drop alone does not prove that SYK is cheap. The latest print of $274.79 remains above the 52-week low of $266.1571, while the stock still carries a 31.5 P/E. Investors should judge the price against the revised earnings outlook, not against the size of one dramatic evening move.
Stryker also has strategic growth projects underway. It completed the ZuriMED acquisition on October 26 to strengthen its shoulder offering and rotator cuff portfolio. On October 12, it announced an alliance with CMR Surgical to advance robotic-assisted surgery. Those initiatives support the long-term story, but they do not offset an immediate guidance reset.
Stryker’s leadership transition also remains scheduled, with Spencer Stiles set to replace Kevin Lobo as CEO on January 1, 2027. The change was well telegraphed, so it is secondary to the earnings catalyst.
SYK’s after-hours fall is a direct response to solid but disappointing quarterly execution and a lower full-year outlook. The company still owns a strong medical-device franchise, yet its premium valuation now demands proof that growth can return to the earlier path.
Investors should weigh the revised guidance, the adjusted-to-reported EPS gap, and the regular-session price action together. That framework separates a potentially overdone reaction from a genuine reset in Stryker’s earnings trajectory.
SYK is down because Stryker reported solid but below-expectation quarterly results and lowered its full-year guidance. Investors are also reacting to the stock’s premium valuation, which leaves less room for disappointment.
+Should I buy SYK stock now?
The article does not support chasing the stock immediately after the drop. Stryker still has strong fundamentals, but the revised outlook means investors should wait for confirmation that earnings growth is stabilizing.
+Did Stryker’s earnings actually grow this quarter?
Yes. Stryker reported 7.7% sales growth and 10.3% adjusted EPS growth in Q3. However, reported EPS fell because of acquisition, amortization, and restructuring costs.
+Is this selloff about the medical-device industry or just Stryker?
This looks like a company-specific reaction, not a broad sector move. The main driver is Stryker’s earnings report and lower 2026 outlook.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on SYK?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.